Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT04837651
Brief Title: Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab (OCR-VAX)

First Submitted : March 16, 2021
First Submitted that Met QC Criteria : April 7, 2021
First Posted : April 8, 2021

Last Update Submitted that Met QC Criteria : July 20, 2021
Last Update Posted : July 27, 2021